Sarepta Therapeutics, Inc.
SRPTHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Sarepta Therapeutics, Inc. (SRPT) is listed under Biotechnology. With a market capitalization of $1.82B, it sits in small-cap territory. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Market Cap
$1.82B
Beta
0.20
P/E (TTM)
49.20
P/E (Fwd)
7.03
EPS (TTM)
$0.35
EPS (Fwd)
$2.45
ROE
4.9%
ROA
0.0%
Cash
$653.2M
Total Debt
$1.05B
Free CF
$204.8M
52W Change
22.3%
Annual Financials
Cash vs Debt
The company holds $653.2M in cash, though total debt stands at $1.05B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $204.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 4.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $933.0M (2022) to $2.20B (2025), reflecting a 136% increase over the period.
With a beta below 0.7, Sarepta Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing SRPT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.